EGFR and lung adenocarcinoma: These efforts become evident by comparing the median overall survival of lung adenocarcinoma patients under standard therapeutic regimes of approximately 12 months with approximately 2 years under EGFR-targeted therapy with Erlotinib or Gefitinib in EGFR-mutated cancers [82].